AstraZeneca (LON:AZN) Earns Buy Rating from Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Berenberg Bank in a research note issued on Tuesday,Digital Look reports. They presently have a £160 price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price objective points to a potential upside of 25.39% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. Citigroup downgraded shares of AstraZeneca to a “buy” rating in a research report on Friday, July 10th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and set a £115 price objective on shares of AstraZeneca in a research report on Friday, June 26th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a £180 price target on shares of AstraZeneca in a research report on Friday, June 26th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of £153.

AstraZeneca Trading Down 1.0%

AstraZeneca stock opened at £127.60 on Tuesday. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66. The business’s fifty day simple moving average is £134.89 and its two-hundred day simple moving average is £140.60. AstraZeneca has a 12 month low of £107.44 and a 12 month high of £157.32. The company has a market capitalization of £197.89 billion, a price-to-earnings ratio of 19.22, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.